Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 848-chemotherapy-without-acute-leukemia-as-secondary-diagnosis-without-cc-mcc
    Ask Trek AI about this page

    Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC: Inpatient Reimbursement Overview

    DRG 848 encompasses inpatient admissions for chemotherapy when acute leukemia is not present as a secondary diagnosis and there are no Complication or Comorbidity or Major Complication or Comorbidity present. This classification defines the expected resource use and sets the standardized Medicare payment rate for such uncomplicated chemotherapy hospital stays.

    Customize your policy alerts

    Sign up for drg 848 policy alerts

    Get alerted when payer policies referencing 848 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 848 Overview

    DRG 848 covers inpatient hospital stays where chemotherapy is the primary reason for admission and acute leukemia is not listed as a secondary diagnosis, without any Complication or Comorbidity or Major Complication or Comorbidity. This Diagnosis-Related Group groups patients with relatively straightforward chemotherapy needs and lower resource use compared with cases that have major complications. It matters for Medicare payment because it establishes the prospective payment rate for these admissions under the inpatient prospective payment system. Accurate assignment affects hospital reimbursement and billing categorization.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating outpatient versus inpatient chemotherapy administration protocols for non-acute leukemia malignancies: These studies compare safety, toxicity monitoring schedules, and resource utilization when systemic chemotherapy is delivered in outpatient infusion centers versus short-stay inpatient admissions for patients without acute leukemia but requiring complex regimens. The patient population includes adults receiving cytotoxic or targeted therapies who have comorbidities or social circumstances that historically prompted inpatient delivery; results inform hospital admission criteria, early-discharge pathways, and payer policy on site-of-care reimbursement.
    • Comparative effectiveness studies of supportive care bundles to reduce admission-related complications: Research in this area tests standardized supportive care interventions (antiemetic and hydration protocols, febrile neutropenia prophylaxis algorithms, and symptom monitoring) among patients hospitalized for chemotherapy without acute leukemia to determine which bundles reduce length of stay, readmissions, and treatment interruptions. The trials typically enroll patients receiving moderately to highly myelosuppressive regimens for solid tumors or hematologic conditions other than acute leukemia; findings are directly relevant to clinicians and payers by identifying protocols that improve safety while lowering hospitalization costs.
    • Post-discharge outcomes and coordination-of-care studies focusing on transitional care and utilization: These observational and interventional studies assess the impact of structured discharge planning, home health nursing, telemonitoring, and early outpatient follow-up on 30-day readmissions, emergency visits, and adherence to subsequent treatment cycles for patients discharged after chemotherapy-only admissions. The population includes patients who required inpatient stays due to treatment administration logistics, toxicity observation, or social determinants; evidence from these studies guides investment in post-acute services and helps payers evaluate value-based reimbursement strategies to reduce avoidable utilization.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.